National Physical Laboratory

How accurately can radioactivity be delivered to tumours?

Researchers from Lund University and NPL have undertaken a detailed study of the measurement uncertainties associated with 177Lu-DOTATATE dosimetry, which is used to treat disseminated neuroendocrine tumours, and (as 177Lu emits both beta particles and gamma photons) can be imaged using single-photon emission computed tomography (SPECT). The study, Uncertainty propagation for SPECT/CT-based renal dosimetry in 177Lu peptide receptor radionuclide therapy, has been published in Physics in Medicine and Biology.

MedicalPhysicsWeb logo

Peptide receptor radionuclide therapy - the use of radiolabelled peptides to deliver radioactivity directly to tumours - is an increasingly-popular cancer therapy. The approach, however, is associated with renal and haematological toxicity, limiting the activity that can be administered. One way to minimise toxicity, while maximising therapeutic activity, is to perform patient-specific dosimetry to determine the absorbed dose to the critical organs.

Read How accurate is 177Lu-DOTATATE dosimetry? on the IOP's Medical Physics Web

Find out more about NPL's Mathematics, Modelling & Simulation research

Find out more about NPL's Radioactivity research

Contact: Maurice Cox

Keep in touch with the latest news and events at NPL
by signing up for an email newsletter

Last Updated: 18 Jan 2016
Created: 7 Dec 2015


Please note that the information will not be divulged to third parties, or used without your permission